Cargando…

Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients

The mPEBev is an anticancer regimen which combines a chemotherapy doublet, based on cisplatin and oral etoposide (mPE), with bevacizumab (mPEBev), a mAb targeting the vasculo-endothelial growth factor (VEGF). In previous studies, this regimen showed powerful anti-angiogenetic effects and significant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martino, EC, Misso, G, Pastina, P, Costantini, S, Vanni, F, Gandolfo, C, Botta, C, Capone, F, Lombardi, A, Pirtoli, L, Tassone, P, Ulivieri, C, Tagliaferri, P, Cusi, MG, Caraglia, M, Correale, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045963/ https://www.ncbi.nlm.nih.gov/pubmed/27752361 http://dx.doi.org/10.1038/cddiscovery.2016.25

Ejemplares similares

The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response
por: Botta, C, et al.
Publicado: (2016)

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)
por: Pastina, Pierpaolo, et al.
Publicado: (2017)

Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine
por: Correale, Pierpaolo, et al.
Publicado: (2018)

Inflammatory status affects the antitumor activity of poly-epitope-peptide vaccination against the thymidylate synthase in metastatic colo-rectal cancer patients enrolled in TSPP/VAC-1 Phase Ib trial
por: Correale, Pierpaolo, et al.
Publicado: (2015)

A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival
por: Botta, C, et al.
Publicado: (2016)

PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach
por: Fameli, Antonella, et al.
Publicado: (2022)

On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer
por: Correale, Pierpaolo, et al.
Publicado: (2020)

GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up
por: Caraglia, Michele, et al.
Publicado: (2019)

How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other Strategies
por: Nardone, Valerio, et al.
Publicado: (2018)

Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer
por: Correale, Pierpaolo, et al.
Publicado: (2012)

Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade
por: Nardone, Valerio, et al.
Publicado: (2021)

The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review
por: Nardone, Valerio, et al.
Publicado: (2023)

Mir-34: A New Weapon Against Cancer?
por: Misso, Gabriella, et al.
Publicado: (2014)

Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities
por: Botta, Cirino, et al.
Publicado: (2014)

Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma
por: Tassone, P, et al.
Publicado: (2012)

Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment
por: Zarone, Mayra Rachele, et al.
Publicado: (2017)

HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
por: Nardone, Valerio, et al.
Publicado: (2021)

Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade
por: Correale, Pierpaolo, et al.
Publicado: (2020)

miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1
por: Amodio, N, et al.
Publicado: (2012)

Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma
por: Scognamiglio, Immacolata, et al.
Publicado: (2014)

Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro
por: Tassone, P, et al.
Publicado: (2003)

CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy
por: Nardone, Valerio, et al.
Publicado: (2021)

Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis
por: Siciliano, M.A., et al.
Publicado: (2022)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

A miRNA signature suggestive of nodal metastases from laryngeal carcinoma
por: Ricciardiello, F., et al.
Publicado: (2017)

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells
por: Botta, C, et al.
Publicado: (2018)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mulcahy, Mary F
Publicado: (2008)

A Hydroquinone-Based Derivative Elicits Apoptosis and Autophagy via Activating a ROS-Dependent Unfolded Protein Response in Human Glioblastoma
por: Zappavigna, Silvia, et al.
Publicado: (2019)

Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects
por: Tenti, Sara, et al.
Publicado: (2020)

Magnetic-Resonance-Imaging Texture Analysis Predicts Early Progression in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiation
por: Nardone, Valerio, et al.
Publicado: (2019)

In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma
por: Di Martino, Maria Teresa, et al.
Publicado: (2014)

miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma
por: Misso, Gabriella, et al.
Publicado: (2019)

Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
por: Tagliaferri, P, et al.
Publicado: (2012)

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2011)

Tumour Burden Reporting in Phase III Clinical Trials of Metastatic Lung, Breast, and Colorectal Cancers: A Systematic Review
por: Santorsola, Mariachiara, et al.
Publicado: (2022)

mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials
por: Rotundo, Maria Saveria, et al.
Publicado: (2016)

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
por: Österlund, P, et al.
Publicado: (2011)

Comment on ‘The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer‘
por: Kitchen, D, et al.
Publicado: (2013)

Bevacizumab-Induced Tumor Vasculature Normalization and Sequential Chemotherapy in Colorectal Cancer: An Interesting and Still Open Question
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8dtvqkj2mgt44cruhb6tr4s94h